COMMUNIQUÉS West-GlobeNewswire

Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura
12/03/2018
Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”) Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”) Further development of Sollpura to be [...]
Extendicare Announces Appointment of Michael Guerriere to Board of Directors
12/03/2018
MARKHAM, Ontario, March 12, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) today announced the appointment of Michael Guerriere to its Board of Directors, effective immediately, [...]
India Globalization Capital Appoints Carrolee Barlow, MD, PhD as Advisor to Help Develop Cannabis Related Products for Treating Various End Points of Parkinson’s Disease and Movement Disorders (PDMD)
12/03/2018
BETHESDA, Md., March 12, 2018 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today announces that Carrolee Barlow, MD, PhD has been appointed to the Company as an Advisor to help develop [...]
Daré Bioscience Announces Exclusive Development and Option Agreement with Orbis Biosciences for Long-acting Injectable Contraceptive
12/03/2018
Advancing 6- and 12- month injectable contraceptive development work carried out to date under a subcontract funded by Family Health International (FHI 360) through a grant from the Bill & Melinda Gates Foundation [...]
Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma
12/03/2018
WATERTOWN, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB ), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding [...]
Epizyme to Participate in Oppenheimer & Co. 28th Annual Healthcare Conference
12/03/2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will present at the [...]
Avivagen Announces Approval from TSX Venture Exchange for Extension of Warrants
12/03/2018
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. OTTAWA, March 12, 2018 (GLOBE NEWSWIRE) -- [...]
Sienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
12/03/2018
-- Trial to Enroll Approximately 30 Patients with Atopic Dermatitis -- Top-Line Results Expected in Fourth Quarter of 2018 WESTLAKE VILLAGE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. ( [...]
PotNetwork Holding Unveils New Products At World’s Premiere Trade Show, ASD Market Week
12/03/2018
FT. LAUDERDALE, Fla., March 12, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- PotNetwork Holding, Inc. (OTC Pink:POTN) (“Company”), announced today that its wholly owned subsidiary, Diamond CBD, Inc., is currently [...]
Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome
12/03/2018
LOS ANGELES, March 12, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR ) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutics that modulate the gut microbiome to treat [...]
Quit smoking, nicotine free: Oriola to distribute Acetium® lozenge in Finland
12/03/2018
Biohit Oyj, Press release, March 12, 2018 at 10:30 am local time (EET) Biohit Oyj and Oriola Oy have signed an agreement for the distribution of the smoking cessation product, Acetium lozenge in Pharmacies and other [...]
Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting
12/03/2018
Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting - Clinical and real-world insights on recombinant human parathyroid hormone ( 1-84) (rhPTH[1-84]) and [...]
Bavarian Nordic Awards Restricted Stock Units to Executive Management
12/03/2018
COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Company has awarded restricted stock units to members of the Executive Management. The Board of Directors of [...]
Bavarian Nordic Announces Annual Report 2017
12/03/2018
COPENHAGEN, Denmark, March 12, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today its Annual Report for 2017. Below is a summary of business progress, financial performance for the year and financial [...]
Novartis announces changes to the Executive Committee to support strategic priorities
12/03/2018
Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger named Chief Ethics, Risk and [...]
Novartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques
12/03/2018
Bertrand Bodson, Chief Digital Officer, est nommé au Comité de direction de Novartis (Executive Committee of Novartis, ECN) Steffen Lang, Global Head Novartis Technical Operations, est nommé à l'ECN Shannon Klinger est [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
12/03/2018
REGULATED INFORMATION GHENT, Belgium, 12 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
IBA SA : IBA signs three new Proteus®ONE contracts with Proton Partners International
12/03/2018
IBA signs three new Proteus ® ONE contracts with Proton Partners International IBA to install three additional Proteus ® ONE compact proton therapy solutions in the UK Louvain-La-Neuve, Belgium, 12 March 2018 - IBA (Ion [...]
IBA SA : IBA signe trois nouveaux contrats Proteus®ONE avec Proton Partners International
12/03/2018
IBA signe trois nouveaux contrats Proteus ® ONE avec Proton Partners International IBA va installer trois solutions compactes de protonthérapie Proteus ® ONE supplémentaires au Royaume-Uni Louvain-la-Neuve, Belgique, 12 [...]

Pages